Indications for and anatomical extent of pelvic lymph node dissection for prostate cancer: Practice patterns of uro-oncologists in North America - Abstract

PURPOSE: To investigate the prevailing practice of uro-oncologists regarding the indications for and extent of pelvic lymph node dissection (PLND) for prostate cancer.

MATERIALS AND METHODS: A 9-question survey was sent as a hyperlink by electronic mail to all members of the Society of Urologic Oncology. Participants were asked about their surgical volume, indications for PLND, which nodal packets are dissected as delineated on anatomical schema, and type of surgical approach.

RESULTS: Of 340 members, 183 urologists (58%) completed the survey. Of these, 43% were ≥10 years out of fellowship and 62% performed >50 radical prostatectomies per year. Of the surveyed surgeons, 45% performed PLND on all patients undergoing radical prostatectomy. The remainder used various risk-stratification schemas. A total of 32 different indications for PLND were reported, the most common being "intermediate risk" according to the American Urological Association's risk classification. As to extent of PLND, 15% perform a PLND limited to the external iliac, while 30% include the external iliac, obturator fossa, and hypogastric lymph nodes. Among surgeons using both open and robotic approaches, 19% reported that the indication for and extent of lymphadenectomy performed differ based on the surgical approach used.

CONCLUSIONS: The results of this survey provide insight into the practice patterns of uro-oncologists regarding PLND and highlight the lack of uniformity in determining when and how a PLND should be performed. Collaborative efforts are needed to develop guidelines on this issue and are a necessary step toward standardization of reporting the outcomes of surgical clinical trials.

Written by:
Touijer KA, Ahallal Y, Guillonneau BD   Are you the author?
Department of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA

Reference: Urol Oncol. 2012 Jun 9
doi:10.1016/j.urolonc.2012.04.021


PubMed Abstract
PMID: 22687569